For individuals at risk, aspirin use is associated with increased risk for incident HF, according to a study published in ESC Heart Failure. Blerim Mujaj, MD, Ph.D., and colleagues conducted a pooled analysis of data from a total of 30,827 individuals (mean age, 66.8±9.2) at risk for HF who were enrolled in six observational studies. Patients were followed for the first incident of fatal or nonfatal HF, while the association of incident HF with aspirin use was examined. The study team found that 1,330 patients experienced HF during a median of 5.3 years. The HR for HF in association with aspirin use was 1.26 in fully adjusted analyses and 1.26 in a propensity-score-matched analysis.
Sacubitril-Valsartan Does Not Cut Risk for HF & Death After MI
For patients with MI, sacubitril valsartan is not associated with a reduced incidence of death from cardiovascular causes or incident HF compared with ramipril, according to a study published in the New England Journal of Medicine. Marc A. Pfeffer, MD, Ph.D., and colleagues randomly assigned patients with MI complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both to receive sacubitril-valsartan or ramipril in addition to recommended therapy. Death from cardiovascular causes or incident HF occurred in 11.9% and 13.2% of patients in the sacubitril-valsartan and ramipril groups, respectively, during a median of 22 months.